by Lisa Willemse | Oct 21, 2013
> If the thought of majestic mountains, impossibly blue skies and natural hot springs isn’t enough to put Banff, Alberta into your calendar this week, then perhaps this preview of the Till & McCulloch Meetings will change your mind. This is the second...
by Mark Curtis | Oct 17, 2013
. Welcome to the first Regenerative Medicine Deal Review, an overview of recent licensing, partnering, and financing activity all exclusively in the regenerative medicine and cell therapy industries. Like my first post ‘Update from the Clinic’, this piece is intended...
by Paul Krzyzanowski | Oct 8, 2013
This is part two of a series on Michael West. Read part one. When most people hear of new applications coming out of stem cell research it’s usually via headline grabbing soon-to-be-products like stem cell derived livers, replacement ears, transplantable retinas,...
by Mark Curtis | Oct 3, 2013
. I have recently joined the business development group at CCRM, as an analyst, and believe it would be useful to start compiling some recaps on clinical developments in the regenerative medicine (RM) and cell therapy industries to complement the other science-related...
by Paul Krzyzanowski | Sep 10, 2013
. Earlier this summer I had the fortunate opportunity to speak with Dr. Michael West, of BioTime, and pick his brain on various aspects of the stem cell industry, what it’s faced, and where it might go. It was a perfect follow up to my post in March that explored...
by Sasha (Alexandra) Lisovsky | Aug 13, 2013
. I was very fortunate to win a CCRM (Centre for Commercialization of Regenerative Medicine) scholarship to attend the 6th Annual “Business of Regenerative Medicine: From Stem Cells to the Market Place” at Case Western Reserve University in Cleveland, Ohio. The focus...
Comments